D Berkovic, W Hiddemann, J Kuduz, E A Fleer
Index: Eur. J. Cancer 33(11) , 1875-80, (1997)
Full Text: HTML
Hexadecylphosphocholine (HePC) is a new etherphospholipid derived substance with pronounced antineoplastic activity. So far the mode of action of this compound has not been resolved. Therefore, we decided to approach this problem by generating HePC resistant sublines of susceptible cells. The human leukaemia cell line HL 60 was successfully adapted to high concentrations of HePC over a period of 14 months. The resistant cell line HL 60 R shows similar functional characteristics as the original HL 60. Both lines can be induced to terminal differentiation into a granulocytic phenotype by DMSO. In this process, normal HL 60 cells also become resistant towards HePC. Determinations of cellular membrane lipid composition did not show significant changes, which would explain the resistance mechanism. Analysis of cellular proteins by 2D-gelelectrophoresis revealed two 50 kDa proteins expressed in HL 60 and differentiated HL 60 cells, which were not expressed in HL 60 R. Reversion of resistance of HL 60 R after prolonged cultivation without HePC led to re-expression of the two proteins, indicating at a possible involvement of these proteins in HePC sensitivity.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
ILMOFOSINE
CAS:83519-04-4 |
C26H56NO5PS |
Phase I trial of ilmofosine as a 24 hour infusion weekly.
2010-01-01 [Invest. New Drugs 13(3) , 205-10, (1995)] |
A phase II trial of ilmofosine in non-small cell bronchogeni...
1996-01-01 [Invest. New Drugs 14(2) , 219-22, (1996)] |
Structure-function relationships of alkyl-lysophospholipid a...
1993-06-01 [Lipids 28(6) , 511-6, (1993)] |
Quaternary ammonium analogs of ether lipids inhibit the acti...
1998-01-01 [Cancer Chemother. Pharmacol. 42(4) , 319-26, (1998)] |
Cytotoxicity of ether phospholipid BM 41.440 on neuroblastom...
1995-01-01 [J. Cancer Res. Clin. Oncol. 121(5) , 262-6, (1995)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved